{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:46:39Z","timestamp":1792539999131,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170159"],"award-info":[{"award-number":["82170159"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA0909300"],"award-info":[{"award-number":["2021YFA0909300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012271","name":"Shenzhen Fundamental Research and Discipline Layout Project","doi-asserted-by":"publisher","award":["JCYJ20210324105007019"],"award-info":[{"award-number":["JCYJ20210324105007019"]}],"id":[{"id":"10.13039\/501100012271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012271","name":"Shenzhen Fundamental Research and Discipline Layout Project","doi-asserted-by":"publisher","award":["JCYJ20220818100412028"],"award-info":[{"award-number":["JCYJ20220818100412028"]}],"id":[{"id":"10.13039\/501100012271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012271","name":"Shenzhen Fundamental Research and Discipline Layout Project","doi-asserted-by":"publisher","award":["JCYJ20220818101404010"],"award-info":[{"award-number":["JCYJ20220818101404010"]}],"id":[{"id":"10.13039\/501100012271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017607","name":"Shenzhen Fundamental Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jbc.2023.104994","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T20:37:00Z","timestamp":1688071020000},"page":"104994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Single amino acid\u2013based PROTACs trigger degradation of the oncogenic kinase BCR\u2013ABL in chronic myeloid leukemia (CML)"],"prefix":"10.1016","volume":"299","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2010-9575","authenticated-orcid":false,"given":"Jianchao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caibing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaowei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7355-3923","authenticated-orcid":false,"given":"Lijing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2023.104994_bib1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210 bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.jbc.2023.104994_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41571-020-0367-1","article-title":"Treatment-free remission in patients with chronic myeloid leukaemia","volume":"17","author":"Ross","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jbc.2023.104994_bib3","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: bcr-ABLBCR-abl","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2023.104994_bib4","doi-asserted-by":"crossref","first-page":"9069","DOI":"10.1074\/jbc.RA120.012821","article-title":"The N-terminal domain of the non-receptor tyrosine kinase ABL confers protein instability and suppresses tumorigenesis","volume":"295","author":"Yan","year":"2020","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2023.104994_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/pharmaceutics14010215","article-title":"BCR-ABL1 Tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia","volume":"14","author":"Amarante-Mendes","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jbc.2023.104994_bib6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2023.104994_bib7","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","article-title":"Flying under the radar: the new wave of BCR\u2013ABL inhibitors","volume":"6","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbc.2023.104994_bib8","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2174\/0929867324666170112112734","article-title":"Kinase inhibitors in multitargeted cancer therapy","volume":"24","author":"Gentile","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jbc.2023.104994_bib9","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.bbapap.2012.12.009","article-title":"Mechanisms of resistance to BCR-ABL and other kinase inhibitors","volume":"1834","author":"Lamontanara","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jbc.2023.104994_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbc.2023.104994_bib11","doi-asserted-by":"crossref","first-page":"7971","DOI":"10.1039\/D2CS00478J","article-title":"PROTAC degraders as chemical probes for studying target biology and target validation","volume":"51","author":"N\u011bmec","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jbc.2023.104994_bib12","first-page":"1","article-title":"PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)","volume":"7","author":"He","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.jbc.2023.104994_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs)\u2014past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Tech."},{"key":"10.1016\/j.jbc.2023.104994_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.crchbi.2022.100020","article-title":"Expanding the landscape of E3 ligases for targeted protein degradation","volume":"2","author":"Kramer","year":"2022","journal-title":"Curr. Res. Chem. Biol."},{"key":"10.1016\/j.jbc.2023.104994_bib15","doi-asserted-by":"crossref","first-page":"8119","DOI":"10.3390\/molecules27238119","article-title":"Current challenges in small molecule proximity-inducing compound development for targeted protein degradation using the ubiquitin proteasomal system","volume":"27","author":"Radhakrishnan","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jbc.2023.104994_bib16","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jbc.2023.104994_bib17","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41388-020-1336-y","article-title":"PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics","volume":"39","author":"Khan","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2023.104994_bib18","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in \u2018beyond rule-of-five\u2019chemical space: recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jbc.2023.104994_bib19","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.molcel.2022.02.004","article-title":"How the ends signal the end: regulation by E3 ubiquitin ligases recognizing protein termini","volume":"82","author":"Sherpa","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jbc.2023.104994_bib20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-biochem-051710-093308","article-title":"The N-end rule pathway","volume":"81","author":"Tasaki","year":"2012","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.jbc.2023.104994_bib21","doi-asserted-by":"crossref","first-page":"15172","DOI":"10.1074\/jbc.AC119.010790","article-title":"A\u00a0modular PROTAC design for target destruction using a degradation signal based on a single amino acid","volume":"294","author":"Shanmugasundaram","year":"2019","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2023.104994_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.3018930","article-title":"In\u00a0vivo half-life of a protein is a function of its amino-terminal residue","volume":"234","author":"Bachmair","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.jbc.2023.104994_bib23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jbc.2023.104994_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1365-2443.1997.1020301.x","article-title":"The N-end rule pathway of protein degradation","volume":"2","author":"Varshavsky","year":"1997","journal-title":"Genes Cells"},{"key":"10.1016\/j.jbc.2023.104994_bib25","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.tibs.2007.08.010","article-title":"The mammalian N-end rule pathway: new insights into its components and physiological roles","volume":"32","author":"Tasaki","year":"2007","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.jbc.2023.104994_bib26","doi-asserted-by":"crossref","first-page":"9281","DOI":"10.1021\/acs.jmedchem.9b01264","article-title":"Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von Hippel\u2013Lindau (VHL) E3 ubiquitin ligase","volume":"62","author":"Zhao","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jbc.2023.104994_bib27","first-page":"1","article-title":"Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies","volume":"13","author":"He","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.jbc.2023.104994_bib28","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng1681","article-title":"Deficiency of UBR1, a ubiquitin ligase of the N-end rule pathway, causes pancreatic dysfunction, malformations and mental retardation (Johanson-Blizzard syndrome)","volume":"37","author":"Zenker","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jbc.2023.104994_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.molcel.2006.08.005","article-title":"Spatiotemporal regulation of c-Fos by ERK5 and the E3 ubiquitin ligase UBR1, and its biological role","volume":"24","author":"Sasaki","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jbc.2023.104994_bib30","doi-asserted-by":"crossref","first-page":"7120","DOI":"10.1128\/MCB.25.16.7120-7136.2005","article-title":"A\u00a0family of mammalian E3 ubiquitin ligases that contain the UBR box motif and recognize N-degrons","volume":"25","author":"Tasaki","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jbc.2023.104994_bib31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1039\/C0MB00074D","article-title":"Impact of linker length on the activity of PROTACs","volume":"7","author":"Cyrus","year":"2011","journal-title":"Mol. BioSystems"},{"key":"10.1016\/j.jbc.2023.104994_bib32","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/17425247.2016.1182485","article-title":"Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications","volume":"13","author":"D\u2019souza","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jbc.2023.104994_bib33","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","article-title":"PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs","volume":"105","author":"Turecek","year":"2016","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.jbc.2023.104994_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0168-3659(01)00331-5","article-title":"PEG drugs: an overview","volume":"74","author":"Greenwald","year":"2001","journal-title":"J.\u00a0Controlled Release"},{"key":"10.1016\/j.jbc.2023.104994_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114442","article-title":"The progress of small-molecules and degraders against BCR-ABL for the treatment of CML","volume":"238","author":"Pan","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jbc.2023.104994_bib36","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1016\/j.bmcl.2016.09.041","article-title":"Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand","volume":"26","author":"Demizu","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jbc.2023.104994_bib37","article-title":"Light-induced control of protein destruction by opto-PROTAC","volume":"6","author":"Liu","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jbc.2023.104994_bib38","doi-asserted-by":"crossref","first-page":"10072","DOI":"10.1039\/D2CC03367D","article-title":"Reactive oxygen species-responsive Pre-PROTAC for tumor-specific protein degradation","volume":"58","author":"Liu","year":"2022","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jbc.2023.104994_bib39","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/cbic.200700438","article-title":"Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: a useful chemical genetic tool","volume":"8","author":"Lee","year":"2007","journal-title":"Chembiochem"},{"key":"10.1016\/j.jbc.2023.104994_bib40","article-title":"PROTAC technology: a new drug design modality for chemical biology with many challenges in drug discovery","volume":"28","author":"Guedeney","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jbc.2023.104994_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114810","article-title":"Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor","volume":"244","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jbc.2023.104994_bib42","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1021\/acs.jmedchem.0c00967","article-title":"Global PROTAC toolbox for degrading BCR\u2013ABL overcomes drug-resistant mutants and adverse effects","volume":"63","author":"Yang","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jbc.2023.104994_bib43","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","article-title":"Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradationdual inhibition and degradation of BCR-ABL1","volume":"79","author":"Burslem","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2023.104994_bib44","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.apsb.2020.11.009","article-title":"Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jbc.2023.104994_bib45","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/cas.13284","article-title":"Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands","volume":"108","author":"Shibata","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jbc.2023.104994_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31913-5","article-title":"Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase","volume":"8","author":"Shibata","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2023.104994_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113645","article-title":"Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation","volume":"223","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jbc.2023.104994_bib48","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region\u2013abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Ren","year":"2013","journal-title":"J.\u00a0Med. Chem."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925823020227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925823020227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:41:19Z","timestamp":1762188079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925823020227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0021925823020227"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2023.104994","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single amino acid\u2013based PROTACs trigger degradation of the oncogenic kinase BCR\u2013ABL in chronic myeloid leukemia (CML)","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2023.104994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"104994"}}